Swedish Orphan Biovitrum AB (publ) (BIOVF)

Market Cap	15.54B +46.7%
Revenue (ttm)	3.06B +8.5%
Net Income	51.86M -87.7%
EPS	0.15 -87.8%
Shares Out	n/a
PE Ratio	299.61
Forward PE	20.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400
Average Volume	519
Open	37.00
Previous Close	36.59
Day's Range	37.00 - 37.00
52-Week Range	25.80 - 37.00
Beta	0.17
RSI	68.52
Earnings Date	Feb 5, 2026

About BIOVF

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1939
• Employees: 1,890
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIOVF

Financial Performance

In 2025, BIOVF's revenue was 28.24 billion, an increase of 8.50% compared to the previous year's 26.03 billion. Earnings were 478.00 million, a decrease of -87.70%.

Financial numbers in SEK